[Sibutramine--antidepressive agent tested against obesity].
Eight European centers recruited 605 obese patients (BMI 30-45 kg/m2) for a six month period of weight loss with sibutramine (10 mg/d) combined with an individualized 600 kcal/d deficit. 467 (77%) patients with > 5% weight loss were then randomized to sibutramine (10 mg/day) and placebo groups over a further 18 months. Initially weight loss progressed to a total of -11.3 +/- 5.5 kg. After randomization the placebo group regained weight to -4.7 +/- 7.2 kg from baseline at 2 years; the sibutramine group only showed slight weight regain to -10.2 kg +/- 9.3 kg (mean group difference 5.5 kg, 95% C.I. 2.9, 8.1, p < 0.001). VLDL fell and HDL increased more than expected by weight loss. Twenty (3%) patients were withdrawn because of increases in blood pressure. This individualized management program achieves metabolically significant and sustained weight loss in 77% of obese patients.
Rössner
S
S
Huddinge Universitetssjukhus. stephan.rossner@medhs.ki.se
D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000494:pharmacology*; D001067:Appetite Depressants / Q000008:administration & dosage / Q000494:pharmacology*; D015992:Body Mass Index; D003503:Cyclobutanes / Q000008:administration & dosage / Q000494:pharmacology*; D004038:Diet, Reducing; D006801:Humans; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D001067:Appetite Depressants; D003503:Cyclobutanes; D017367:Selective Serotonin Reuptake Inhibitors; C058254:sibutramine